RxDoctor Payments Data

Britney Russell

Nurse Practitioner · Raleigh, NCNPI 1356768428

Payments from drug & device makers

$1,123in general payments, 2019–2025

Across 37 payments — averaging $30.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$451
  • AstraZeneca$233
  • Amgen$128
  • GSK$48
  • Johnson & Johnson$40
  • Akebia Therapeutics Inc$36
  • plus $188 from 9 others

What the payments were for

  • Food & beverage$1,121100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,123 in reported general payments places this provider in the 75th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$12,319
Medicare patients
69
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide13$38,303
Sevelamer Carbonate82$9,663
LokelmaSodium Zirconium Cyclosilicate12$7,130
Combivent RespimatIpratropium/Albuterol Sulfate15$6,994
Calcium Acetate27$2,353
Midodrine Hcl27$1,158
Lidocaine-PrilocaineLidocaine/Prilocaine27$893
Hydralazine Hcl31$548
Carvedilol47$456
Albuterol Sulfate HfaAlbuterol Sulfate17$352
Amlodipine Besylate54$324
Bumetanide16$320
Gabapentin28$301
Mirtazapine22$294
Torsemide13$265

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$451$38,30313 claims
AstraZenecaLokelma$233$7,13012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →